Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Drinking coffee may help prevent diabetes, report scientists

Scientists are reporting new evidence that drinking coffee may help prevent diabetes and that caffeine may be the ingredient largely responsible for this effect. Their findings, among the first animal studies to demonstrate this apparent link, appear in ACS' bi-weekly Journal of Agricultural and Food Chemistry.

10 Jun 2010

Fero Industries enters into Asset Acquisition Agreement with GVEST

Fero Industries, Inc. is pleased to announce that it has entered into an Asset Acquisition Agreement with GVEST Inc., an Ontario Corporation, for the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

10 Jun 2010

Penn State study: Young girls who drink soda have less healthy diets through adolescence

Young girls who drink soda have less healthy diets through adolescence than their peers who do not drink soda, according to a Penn State study. The ten-year study showed that girls who drank soda at age five had diets that were less likely to meet nutritional standards for the duration of the study, which ended at age 15. Girls who did not drink soda at age five did not meet certain nutritional requirements, but their diets were healthier.

9 Jun 2010

Insulin delivery devices help diabetic patients optimize blood glucose control, minimize chronic health problems

The growing use of insulin delivery devices such as pens and pumps may help individuals with diabetes optimize blood glucose control and minimize their risk for chronic health problems associated with diabetes, as described in a Special Supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc.

9 Jun 2010

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Melior Discovery, Inc. announced today the United States Patent and Trademark Office (USTPO) has awarded a Notice of Allowance for a broad patent application covering the Company's use of MLR-1023 for, among other things, the treatment of type II diabetes and obesity. The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as a component in other drugs.

8 Jun 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS, Inc. today announced that data from a previously reported phase 2 study evaluating the safety and efficacy of the investigational drug Qnexa for the treatment of obstructive sleep apnea were presented at SLEEP 2010, the 24th Annual Meeting of the Associated Professional Sleep Societies.

8 Jun 2010

Value-based wellness programs for patients with metabolic syndrome

HealthInsight, provider of the leading health incentive platform, today announced a new addition to its value-based wellness programs for patients with metabolic syndrome. The program is designed to detect and manage the syndrome's symptoms before the condition becomes chronic, thereby allowing individuals to take preventive action and manage their overall health while reducing on-going treatment costs.

8 Jun 2010

Boosting levels of ABCG1 protein in diabetics will improve insulin production

If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia.

8 Jun 2010

La Jolla Institute scientist finds protein key to insulin secretion

8 Jun 2010

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Depomed, Inc. today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

8 Jun 2010

Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today reported preliminary outcomes and trends from the ongoing Phase III pivotal study of Generex Oral-lyn, the Company's proprietary oral insulin spray product.

7 Jun 2010

Harbor BioSciences to raise $2.06M through sale of common stock shares and warrants

Harbor BioSciences, Inc. announced today that it has entered into an agreement with certain institutional investors to raise approximately $2.06 million in gross proceeds through the sale of approximately 5.9 million shares of its common stock and warrants to purchase approximately 3.5 million shares of its common stock.

7 Jun 2010

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

VIVUS, Inc. today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.

7 Jun 2010

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Kineta, Inc. joined with The Iacocca Family Foundation today to announce a new investment partnership to speed development of Kineta's preclinical autoimmune drug candidate - ShK-186 - and its multiple applications to treat Type 1 diabetes mellitus.

7 Jun 2010

Key regulator of fat cell differentiation identified

New research led by UCD Conway Fellow, Professor Johan Ericsson has identified a key regulator of fat cell differentiation that may be a novel target for obesity drugs. The results of the research are published in the current edition of the scientific journal, Proceedings of the National Academy of Sciences (PNAS).

4 Jun 2010

Researchers find a way to isolate pancreatic islet cells from brain dead donors using DI

A team of researchers from several collaborating Baylor University research centers and from Japan's Okayama Graduate School of Medicine have found a way to more consistently isolate pancreatic islet cells from brain dead donors using ductal injection, a process that immediately cools donor islet cells at the injection site.

4 Jun 2010

Testosterone deficiency can lead to multiple disorders

Almost a quarter of men treated for cancer in their childhood suffer from a deficiency of the male sex hormone testosterone.

3 Jun 2010

Community interventions help American Indian families reduce early childhood weight gain: Study

Community intervention can help American Indian families change behavior related to early childhood weight gain and obesity, according to a new Kaiser Permanente and Northwest Portland Area Indian Health Board study.

3 Jun 2010

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Drinking coffee may help prevent diabetes, report scientists

Fero Industries enters into Asset Acquisition Agreement with GVEST

Penn State study: Young girls who drink soda have less healthy diets through adolescence

Insulin delivery devices help diabetic patients optimize blood glucose control, minimize chronic health problems

USTPO awards Melior Discovery Notice of Allowance for type II diabetes and obesity drug candidate

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Value-based wellness programs for patients with metabolic syndrome

Boosting levels of ABCG1 protein in diabetics will improve insulin production

La Jolla Institute scientist finds protein key to insulin secretion

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported

Harbor BioSciences to raise $2.06M through sale of common stock shares and warrants

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

The Iacocca Family Foundation and Kineta partner to develop Type 1 diabetes mellitus drug

Key regulator of fat cell differentiation identified

Researchers find a way to isolate pancreatic islet cells from brain dead donors using DI

Testosterone deficiency can lead to multiple disorders

Community interventions help American Indian families reduce early childhood weight gain: Study

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in